Black Diamond Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
BDTX$1.60-14.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(82,442) | $(91,169) |
| Adjustment to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 9,604 | 12,197 |
| Depreciation expense | 437 | 508 |
| (Accretion) amortization on investments | (1,174) | 536 |
| Noncash rent expense | 2,814 | 2,730 |
| Loss on disposal of property and equipment | 358 | — |
| Gain on sale of property and equipment | — | (1) |
| Gain on sale of IP | — | (2,232) |
| Equity in losses of unconsolidated entities | — | 2,250 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 2,265 | 1,018 |
| Other non-current assets | — | 16 |
| Accounts payable | 597 | (2,230) |
| Accrued expenses and other current liabilities | 3,938 | (5,864) |
| Non-current operating lease liability | (3,114) | (2,841) |
| Net cash used in operating activities | (66,717) | (85,082) |
| Cash flows from investing activities: | ||
| Purchases of equipment | (33) | (192) |
| Proceeds from disposal of equipment | 95 | 9 |
| Proceeds from sales and maturities of investments | 78,171 | 113,690 |
| Purchases of investments | (61,887) | (60,141) |
| Net cash provided by investing activities | 16,346 | 53,366 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of common stock options and ESPP | 82 | 177 |
| Proceeds from issuance of common stock, net of issuance costs | 71,850 | — |
| Net cash provided by financing activities | 71,932 | 177 |
| Net increase (decrease) in cash and cash equivalents | 21,561 | (31,539) |
| Cash, cash equivalents and restricted cash, beginning of year | 35,483 | 67,022 |
| Cash, cash equivalents and restricted cash, end of year | $57,044 | $35,483 |
| Cash and cash equivalents, end of year | $56,221 | $34,315 |
| Restricted cash, end of year | 823 | 1,168 |
| Cash, cash equivalents and restricted cash, end of year | $57,044 | $35,483 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Right-of-use assets obtained in exchange for operating lease obligation | $— | $(181) |
| Equity method investment acquired for non-cash consideration | $— | $18 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.